CHALLENGES IN FEMORO-POPLITEAL STENTING

Similar documents
Is a Stent or Scaffold Necessary in The SFA?

Christian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide

Robert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015

Clinically proven. ordering info. Vascular Intervention // Peripheral Self-Expanding Stent System/0.018 /OTW. Pulsar-18

Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA

New Data to Shape the Era of Drug Elution in Peripheral Interventions

When Outcomes Matter, Design Matters

Disclosures. In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA

Superficial Femoral Artery Intervention: The gift that keeps on giving! Wm. Britton Eaves,MD WKHSC Bossier City, LA

BioMimics 3D in my Clinical Practice

SFA lesion treatment: China experience. Wei Liang, MD

Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis

4/14/2016. Faculty Disclosure. Drug-eluting technology in the SFA and Popliteal. Typical SFA Disease Pattern. Why Peripheral Artery Disease Matters

Accurate Vessel Sizing Drives Clinical Results. IVUS In the Periphery

The Crack and Pave technique for highly resistant calcified lesions. Manuela Matschuck MD University Hospital Leipzig Department Angiology

Update in femoral angioplasty & stenting PRO

MEET M. Bosiers K. Deloose P. Peeters. SFA stenting in 2009 : The good and the ugly What factors influence patency?

Tools and options for recanalisation of long-femoro-popliteal segments

Lessons learnt from DES in the SFA is there any ideal concept so far?

Interventional Radiology in Peripheral Vascular Disease: How Far Can We Go? Dr. L. F. CHENG Department of Radiology Princess Margaret Hospital

Mechanical Properties of the GORE TIGRIS Vascular Stent

Management of In-stent Restenosis after Lower Extremity Endovascular Procedures

Sustained Release. Superior Results.

Treatment Strategies for Long Lesions of greater than 20 cm

Minimizing Burden, the effect of thin strut and low Chronic Outward Force SE stents

Drug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND

Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD

2-YEAR DATA SUPERA POPLITEAL REAL WORLD

Disclosures. Rational Selection of Endovascular Options for the SFA and Popliteal: What Works Where and for How Long?

THE NEW ARMENIAN MEDICAL JOURNAL

The drug-eluting balloon superficial femoral artery-long study THE DEB SFA-LONG STUDY

Utility of Image-Guided Atherectomy for Optimal Treatment of Ambiguous Lesions by Angiography

Evolving Role of Drug-Eluting Stents In Complex SFA - Majestic Trial Data

Lessons & Perspectives: What is the role of Cryoplasty in SFA Intervention?

5-YEAR SUPERIOR RESULTS. Compared to PTA and Zilver BMS 1. NOW WITH 140 mm LENGTH STENTS

Clinical benefits on DES Patient s perspectives

The drug-eluting balloon superficial femoral artery-long study THE DEB SFA-LONG STUDY

TOBA Trial 12 months Results

Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?

TOBA II 12-Month Results Tack Optimized Balloon Angioplasty

The BATTLE Trial Comparing Bare Metal to Drug Eluting Stents for Intermediate Length Lesions of the SFA

The latest evidences from the DES trials in peripheral arterial disease

Does stent design influence the results of SFA stenting?

The Final Triumph Of Endovascular Therapy In SFA Treatment

Excimer Laser angioplasty for femoro-popliteal disease. Sendai Kousei Hospital, Tokyo Kamata Hospital Naoto Inoue MD, FSCAI, FJCC, FAHA

A Data-driven Therapeutic Algorithm For Choosing Among Currently Available Tools For SFA Intervention

BIOFLEX PEACE Registry

Medical therapy after angioplasty / stenting

Update on the Levant 2 Clinical Trial Programme. Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany

Disclosures. In-Stent Restenosis: The Tail IS Wagging the Dog 4/15/2016. Restenosis: The Continuing Challenge for Peripheral Vascular Intervention

Long-term results with interwoven nitinol stents vs. BMS vs. DCB

The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions

Stents for Femoropopliteal Disease:

Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA

Recent Advances in Peripheral Salvage

The present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio

Neuestes aus der Therapie der pavk. beschichtete Stents + Ballons. Karls-University. Eberhard-Karls. of Tubingen Department of Diagnostic Radiology

Latest Insights from the LEVANT II study and sub-group analysis

Update on the Ranger clinical trial programme

Paclitaxel Drug-Eluting Stents in Peripheral Arterial Disease: A Health Technology Assessment

Atherectomy is Still Live and Effective. John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System

Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results

Hybrid Heparin-Bonded Nitinol and eptfe Stent in the treatment of popliteal artery occlusion: mid- term follow-up results.

Turbo-Power. Laser atherectomy catheter. The standard. for ISR

Drug Elution, Data, and Decisions

Evidence-Based Optimal Treatment for SFA Disease

Could a combination of DCB + stent be the answer in complex SFA lesions

The latest generation DEB

Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria

The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report

Current Status of Drug-Eluting Stents and Drug-Eluting Balloons for the Superficial Femoral Artery

Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD

The role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium

Update on the OPTIMIZE BTK Trial. Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria

Future Devices of Venous Interventions

TurboHawk. Plaque Excision System

Or is the ivolution stent a better alternative? EVOLUTION 12-month data

REACT Treatment Rationale and Clinical Evidence. ICI Meeting 5th of December 2017

INTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY. VascuFlex Peripheral Stent Systems. Self-Expanding Peripheral Nitinol Stents

DCB level 1 evidence review

Stents for The Common Femoral Artery: The Good, The Bad and The Ugly

Cutting/scoring balloon Cryoplasty Drug-eluting balloon Brachytherapy Debulking Restent (BMS or DES) John R. Laird, MD

Pulsar stent technology

Chronic Total Occlusion (CTO) Technologies

Surgical Bypass or. Zilver PTX. 12 months preliminary data. LINC 2016, Leipzig. Marc Bosiers, MD. Marc Bosiers Koen Deloose Joren Callaert

Intervention for Lower Extremity PAD: When, why and what?! Robert F Cuff, MD FACS RVT RPVI

Experience With Atherectomy and DCBs

Brachytherapy for In-Stent Restenosis: Is the Concept Still Alive? Matthew T. Menard, M.D. Brigham and Women s Hospital Boston, Massachussetts

Drug- Coated Balloons for the SFA: Overview of Technology and Results

Present & future of below the knee stenting

Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

Merits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁

NEW DAWN: 1-year results of the combination DCBs and Supera stent for the treatment of long femoropoliteal lesions

Do we really need a stent in long SFA lesions? No: DEB is the answer

Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)

Hypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis

Atherectomy: Jetstream and Directional. George S. Chrysant, M.D.

Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort

Transcription:

CHALLENGES IN FEMORO-POPLITEAL STENTING Karathanos C MD, MSc, PhD, Athanasoulas A, Rousas N, Spanos K, Giannoukas A Department of Vascular Surgery, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

Peripheral Artery Disease (PAD) INCIDENCE Superficial Femoral Artery (SFA)- 50% Popliteal Artery (PA)

A B Usually PTA PTA preferred Endo or Medical Endo or Medical Treatment Consideration: Anatomic status C D Surgery preferred Usually surgery Endo or Medical or Open Open or Endo or Medical

Metalic stents-nitinol stents- e-ptfe covered stents- Drug eluting stents- Bioabsornable stents

The name comes from the components of the alloy (Ni and Ti) and initial laboratory Naval Ordnance Laboratory The starting alloy containing 55% Ni and 45% Ti, (01/01 ratio of atoms of the two components.)

They are superelastic (crush recoverable) Full elastic recovery after yet and greater than 10% deformation

PLASTIC DEFORMATION If the force applied is greater than a limit (yield point), then some bonds between atoms are broken, people are moved and new links are created. The end result is a permanent change of shape.

ELASTIC DEFORMATION The metal atoms are moved slightly together, but after removal of the force revert to the previous position. Thus, the wire (STENT) changes shape as the force effect, but then resumes its original shape.

S T R E S S STRAIN

Superelastic NiTi: Superelastic NiTi wires have a flat response in the elastic region. That is, the force exerted by a superelastic wire is the same in large deformation range A superelastic spring continuously exerts the same force and a common spring will exercise great power in the beginning, which will decrease as the artery open

Flat unloading curve over a wide deflection (strain) range Importance Exercise constant force in the artery regardless of their level of deployment Exert a gentle chronic outward force Continuing external pressure in the artery until they acquire their diameter. If the artery is stretched will follow further opening of the stent

Nitinol Properties Kink Resistance

Remembering shape The Ni-Ti wires have the property of returning to a former shape when heated above a certain temperature. The temperature depends on the manufacturing conditions and the proportion of cobalt. Usually the Co is 1.6%

Temperature - dependent stiffness Nitinol stents with a transition temperature of 30 C Weak when squeezed at low temperature. Much stiffer when squeezed at T above 30

Presently Most self-expanding Nitinol stents are produced by laser cutting of Nitinol tubing.

Laser-cut Nitinol tubular stents. Top: Memotherm (Bard Angiomed) bottom: SMART (Cordis) Laser-cut Nitinol tubular stents. Top: Jostent SelfX (Jomed) bottom: DynaLink (Guidant)

Mechanical stent fatigue or/and fracture is emerging as one of the critical issues for the stenting procedure success Reported incidence and clinical relevance of femoropopliteal stent fractures vary across studies Stent fracture may lead to repeat revascularization due to in-stent restenosis.

Multiple lesions are the most critical condition since the strain values are higher Highest deformation are concentrated between two stenoses were the stiffness of the vessel is lower Suggests the use of multiple stents to cover a double peak plaque, instead of a single long stent, that might be subjected to high deformation between the two stenoses Longer stents are more prone to fracture Stent is more prone to fracture under axial compression than bending, especially for distal SFAproximal Pop A

OBJECTIVES: To evaluate longer-term safety and efficacy of a single self-expanding stent up to 20 cm in length in patients with atherosclerotic disease of the superficial femoral (SFA) and proximal popliteal arteries. METHODS: 287 patients (mean age 68 years, 66% male) were treated with the EverFlex Self-Expanding Peripheral Stent System. Patients were followed through 3 years with yearly core lab adjudicated duplex ultrasonography for patency, radiographic assessment of stent fractures, and resting ankle brachial indices. RESULTS: Overall freedom from loss of primary patency at 3 years was 60.0%. Patency was significantly higher for lesions 8 cm compared with lesions >8 cm (71.0 vs. 50.5%, P < 0.0001). There was no significant difference in patency between single-stent and multistent recipients (60.4 vs. 52.4%, P = 0.343). The three-year freedom from clinically driven target lesion revascularization was 70.0%. At 3 years, the overall stent fracture rate was 0.9%. CONCLUSIONS: DURABILITY II is the first investigational device exemption trial to report 3- year duplex Doppler defined stent patency and CD-TLR outcomes in long SFA and proximal popliteal lesions and demonstrated acceptable stent patency and freedom from CD-TLR with a low fracture rate. These data suggest that use of a single long stent provides reasonable long-term outcomes when intervention is required for symptomatic SFA and proximal popliteal arterial disease

6 closed-end interwoven nitinol wires

The Supera Vascular Mimetic Implant: Mimics the natural structure and movement of the anatomy Maintains a visibly round, open lumen for normal, healthy blood flow in challenging anatomy

Provides the highest levels of both strength and flexibility for a durable solution Provides the strength needed to treat highly calcified lesions with the lowest chronic outward force 4x the compression resistance 86% primary patency at 1 year in the SUPERB trial

METHODS AND RESULTS: 527 limbs in 470 patients with femoropopliteal arterial disease were treated with SUPERA stents. The primary patency (PP) rates were 83.3% after 12 months and 72.8% at two years. The secondary patency rates were 98.1% after 12 months and 92.0% at two years. Patency rates did not differ between superficial femoral artery (SFA) and popliteal lesions. Between baseline and a mean of 21 months of follow-up, mean ABI increased from 0.53 to 0.91, and mean RBC decreased from 3.0 to 1.9 (p<0.001 for both comparisons). Radiographs performed on 229 patients at a mean of 16.6 months confirmed the absence of stent fractures in all patients. CONCLUSIONS: Over a two-year surveillance period, the patency rate and fracture resistance of SUPERA stents implanted for complex femoropopliteal artery disease were high.

Ansel GM. J Endovasc Ther. 2009;16(Suppl II):II82 II97

Sirolimus-eluting stents (SMART stents) Paclitaxel-eluting non polymer-based stent (Zilver PTX) Self-expanding polymerbased everolimus-eluting stent (Dynalink-E)